Author: BusinessWire

March 9, 2021 Off

Fezolinetant (ESN364): Astellas’ Neurokinin 3 Receptor Antagonists Under Development for the Treatment of Vasomotor Symptoms – Global Emerging Insight and Market Forecast to 2030 – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Fezolinetant (ESN364) – Emerging Insight and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.

“Fezolinetant (ESN364) – Emerging Insight and Market Forecast – 2030” the report provides co…

March 9, 2021 Off

Fezolinetant (ESN364): Astellas’ Neurokinin 3 Receptor Antagonists Under Development for the Treatment of Vasomotor Symptoms – Global Emerging Insight and Market Forecast to 2030 – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Fezolinetant (ESN364) – Emerging Insight and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.

“Fezolinetant (ESN364) – Emerging Insight and Market Forecast – 2030” the report provides co…

March 9, 2021 Off

Fezolinetant (ESN364): Astellas’ Neurokinin 3 Receptor Antagonists Under Development for the Treatment of Vasomotor Symptoms – Global Emerging Insight and Market Forecast to 2030 – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Fezolinetant (ESN364) – Emerging Insight and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.

“Fezolinetant (ESN364) – Emerging Insight and Market Forecast – 2030” the report provides co…

March 9, 2021 Off

Cybin Announces API Synthesis and Optimization of Multiple Tryptamine Derivatives and Nomination of Two Deuterated Candidates for Full IND Enabling Studies Based on Second Milestone Achievement Pursuant to the Adelia Acquisition

By BusinessWire

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a life sciences company focused on psychedelic pharmaceutical t…